查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1195547

消融设备市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Ablation Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

消融设备市场预计在预测期内 (2023-2028) 的复合年增长率为 10.4%。

由于 COVID-19 大流行，医疗保健系统面临着巨大挑战。 在 COVID-19 流行期间，大多数慢性病护理被认为是非紧急护理，所有门诊护理都被推迟或限制，以降低病毒传播的风险。 根据 2022 年 5 月发表在 Authorea 上的一篇论文“在 COVID-19 大流行期间导管消融相关不良事件的报告率下降”，报告的缺陷从 2019-2020 年到 2020-2021 年观察到具有统计学意义的减少。 本文调查了美国食品和药物管理局製造商和用户设施设备的经验，以确定与经皮心臟消融导管相关的房颤治疗失败、经皮心臟消融导管治疗心房颤动相关的失败以及心房扑动的治疗显示，本次疫情期间经皮心臟消融导管相关损伤报告率明显下降。 在 COVID-19 大流行期间，所有非紧急择期手术都已暂停，导致与往年相比，在此期间进行的消融手术数量非常少。 因此，COVID-19 大流行对市场的增长产生了重大影响。

癌症、心血管疾病和其他眼科、妇科和泌尿科疾病等主要慢性病在全球范围内呈上升趋势，推动了消融设备市场的增长。 此外，随着风险的增加，已经出现了有效治疗慢性病患者的有效手术方式。 慢性病的日益流行在医疗保健中发挥着重要作用。

由于慢性病的增加，越来越多的因素也在提高消融设备领域的市场份额。 例如，癌症是全世界死亡的主要原因之一，预计到 2020 年将导致约 1000 万人死亡。 根据 GLOBOCAN 2020 报告，2020 年全球癌症患者总数约为 19,292,789 人。 据估计，到 2040 年将增加到 28,887,940 人。 根据国际糖尿病联合会《糖尿病地图集第十版2021》，2021年全球约有5.37亿成年人被诊断患有糖尿病，到2030年将达到6.43亿。到2045年，这一数字预计将增加到7.83亿。 全球慢性病的增加预计将推动研究目标市场的增长。

一些专注于创新消融设备的研发研究也在推动血流设备测量市场的增长。 例如，2021 年 5 月，Acutus Medical 启动了一项前瞻性、多中心、非随机的国际临床试验，旨在证明 AcQBlate 力传感系统的安全性和性能。 AcQBlate 力传感系统是用于心律失常的电生理标测和射频消融的完整且差异化的解决方案。 这项研究将侧重于可及肺静脉的导管消融，最终目标是为每条肺静脉建立有针对性的电隔离，预计将于 2024 年 1 月完成。 预计消融设备开发研究的增加将在预测期内推动消融设备市场的增长。

消融领域主要参与者的不断发展也刺激了市场增长。 例如，2021 年 11 月，Hologic 推出了 NovaSure V5，这是美国研究最多和最值得信赖的子宫内膜消融（ GEA ）设备。 此类设备的研究和开发不断增加，预计将推动市场的增长。

全球对消融设备日益增长的需求预计将推动消融设备市场的增长。 然而，该设备的高成本、严格的法规和消融设备的低意识可能会阻碍市场增长。

消融设备市场趋势

在消融设备市场，癌症治疗领域预计将占据主要市场份额。

癌症治疗是消融设备市场的一个主要部分。 全球癌症患者数量的增加也刺激了消融设备市场的发展。 世界癌症研究基金会国际组织在其 2022 年 3 月更新的全球癌症数据中指出，到 2020 年，全球估计将有 1810 万癌症患者。 其中，男性为 930 万，女性为 880 万。 多年来病例数量的显着增加极大地促进了癌症手术的增加，以进行有效的治疗研究，这很可能在预测期内推动消融设备市场的增长。

根据 2021 年 2 月更新的 RadiologyInfo.org 文章，射频消融术 (RFA) 是一种微创癌症治疗方法，它使用一种图像引导技术，利用热量来破坏癌细胞。我们正在招聘。 RFA利用超声波、CT（计算机断层扫描）、MRI（磁共振成像）等将针状电极引导至癌性肿瘤，通过电极，高频电流通过放置在其上的接地垫身体，它会产生集中的热量，破坏电极周围的癌细胞。 该文章还表明，射频和微波消融是癌症治疗中最常用的消融方式。

此外，多个市场参与者正在关注癌症市场的消融设备。 例如，2022 年 5 月，Avenda Health 的 iQuest 在 2022 年美国泌尿外科协会年会上宣布，一项回顾性研究表明，与传统治疗方案相比，iQuest 将肿瘤包封率从 56% 提高到 80%。 2021 年 5 月，美国食品和药物管理局宣布了一项由总部位于加利福尼亚州的软件和医疗设备公司 Avenda Health 开发的前列腺癌治疗方法，该方法使用人工智能 (AI) 和微创技术来改善癌癥结果。该技术被指定为突破性设备. Avenda Health 焦点治疗系统是一种支持人工智能（ AI ）的焦点治疗系统，正在开髮用于通过局部麻醉治疗局部前列腺癌。 除了依赖于大型图像和病理数据库的基于人工智能的边缘预测算法外，该设备还使用激光和独特的光学和热传感器来精确定位和治疗前列腺肿瘤。 这种靶向消融设备的目的是在不损害其他身体功能的情况下，最大限度地减少对健康组织的影响。 预计此类消融设备的研发将在预测期内推动市场增长。

北美将占据很大的市场份额，预计在预测期内（2022 年至 2027 年）也将如此。

在消融设备製造中越来越多地采用先进技术和系统，以及消融设备研究方面的技术进步预计将推动北美地区的市场增长。 人们对市场上创新消融设备治疗的可用性的高度认识有助于该地区的高市场增长。

北美地区越来越多的慢性病患者正在刺激消融设备市场的增长。 癌症是美国十大死因之一。 根据 GLOBOCAN 2020 报告，2020 年美国癌症患者总数将约占 2,281,658 人。 据估计，到 2040 年将增加到 3,123,452。 根据 2022 年 1 月更新的国家糖尿病统计报告，美国已知约有 3730 万人患有糖尿病，约有 9600 万成年人处于糖尿病前期。 国家肾臟基金会 2021 年估计，美国约有 3700 万成年人患有慢性肾病。 美国疾病控制与预防中心 2020 年的一份报告发现，约有 1570 万美国人患有慢性下呼吸道疾病。 患有慢性病的大量人口以及对消融设备以促进此类疾病的诊断和治疗的需求不断增加，预计将推动消融设备市场的增长。

该地区创新消融设备的不断发展也推动了市场的增长。 例如，2020 年 7 月，美国食品和药物管理局授予了一项突破性设备称号，用于经支气管微波消融技术，该技术使用了强生医疗器械公司子公司 Ethicon 开发的机器人辅助支气管镜。我在这里。 消融设备的此类技术创新和不断增加的监管批准有望在预测期内推动消融设备市场的增长。

因此，众所周知，对消融设备不断增长的需求以及对医疗行业投资的增加将推动该地区的市场增长。

消融设备市场竞争对手分析

全球消融设备市场竞争适中，由几家主要参与者组成。Abbott、AngioDynamics, Inc、AtriCure, Inc、Boston Scientific Corporation、BTG plc、Conmed Corporation、Johnson and Johnson、Medtronic PLC、Olympus Corporation、Smith &Nephew PLC诸如此类的公司在消融设备市场中占有相当大的市场份额。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 慢性病增加
    • 技术进步
    • 下一代消融产品和技术的出现
  • 市场製约因素
    • 设备成本高
    • 认知度低，监管严格
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按设备技术
    • 高频设备
    • 激光/光学烧蚀
    • 超声波设备
    • 冷冻消融设备
    • 其他设备
  • 通过申请
    • 癌症治疗
    • 心血管疾病治疗
    • 眼科治疗
    • 妇科治疗
    • 泌尿外科治疗
    • 整容手术
    • 其他
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Abbott Laboratories
    • Alcon Laboratories
    • AngioDynamics, Inc.
    • AtriCure, Inc.
    • Bausch & Lomb Incorporated
    • Biotronik
    • Boston Scientific Corporation
    • Conmed Corporation
    • Johnson and Johnson
    • Medtronic PLC
    • Olympus Corporation
    • Smith & Nephew PLC

第7章 市场机会与今后动向

简介目录
Product Code: 67243

The Ablation Devices Market is projected to register a CAGR of 10.4% during the forecast period (2023 - 2028).

The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to ​reduce the risk of viral transmission, as most chronic therapies were regarded as non-urgent. An article titled "Decrease in Reported Rates of Catheter Ablation-Related Adverse Events During the COVID-19 Pandemic" published in the journal of Authorea in May 2022 indicated that there was a statistically significant drop in reported malfunctions from the year 2019 - 2020 to 2020 - 2021. The article examined the United States Food and Drug Administration Manufacturer and User Facility Device Experience and illustrated that there were significant decreases in reported rates of malfunctions associated with cardiac ablation percutaneous catheters, malfunctions associated with cardiac ablation percutaneous catheters for the treatment of atrial fibrillation, and injuries associated with cardiac ablation percutaneous catheters for the treatment of atrial flutter during the pandemic. Due to the suspension of all non-urgent elective surgical operations during the COVID-19 pandemic, the number of ablation surgeries performed during the period is very less compared to that of the previous year. Thus, the COVID-19 pandemic significantly impacted the growth of the market.

The major chronic diseases such as cancer, cardiovascular diseases, and other ophthalmologic, gynecological, and urological diseases are on the rise all over the world, which is adding to the growth of the ablation devices market.​With increasing risks, there are also effective surgical therapies that lead to the efficient treatment of patients suffering from chronic illness. The rise in the number of chronic disease cases plays an important role in healthcare.

In addition, the growing number of factors attributing to the rise in chronic disease is increasing the market share for the ablation devices segment. For instance, cancer is one of the leading causes of death all around the world, accounting for around 10 million deaths in 2020. According to the GLOBOCAN 2020 report, the total number of people in the world affected by cancer in 2020 accounts for around 19,292,789 cases. The number is estimated to rise to 28,887,940 cases by 2040. ​Also, according to the International Diabetes Federation Diabetes Atlas Tenth edition 2021, in 2021, around 537 million adults all over the world were found to have diabetes, with the numbers projected to grow to 643 million by 2030 and 783 million by 2045. The rise in the number of chronic diseases all over the world is expected to propel the growth of the studied market.

Several research and development studies focusing on innovative Ablation Devices are also adding to the growth of the blood flow device measurement market. For instance, in May 2021, Acutus Medical initiated a prospective, multi-center, non-randomized global clinical study designed to demonstrate the safety and performance of the AcQBlate Force Sensing System. AcQBlate Force Sensing System is a complete and differentiated solution for the electrophysiologic mapping and radiofrequency ablation of cardiac arrhythmias. The study focuses on the catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein and is expected to be completed by January 2024. The increasing research in the development of ablation devices is expected to boost the growth of the ablation devices market in the forecast period.

The increasing developments made among the key players in the ablation segment are also adding to the growth of the market. For instance, in November 2021, Hologic, Inc. launched the NovaSure V5 global endometrial ablation (GEA) device, the most studied and trusted endometrial ablation procedure in the United States. The rise in the research and development of such devices is expected to boost market growth.

The increase in the necessity of ablation devices around the world is expected to propel the growth of the ablation devices market.​ However, the high cost of the devices and the strict regulations, coupled with the lack of awareness about ablation devices, are likely to hinder the market growth.

Ablation Devices Market Trends

The Cancer Treatment Segment is Expected to Hold a Major Market Share in the Ablation Devices Market.

Cancer treatment holds the major segment in the ablation devices market. The rising number of cancer cases around the world is also adding to the developments in the ablation devices market. The World Cancer Research Fund International, in its Worldwide Cancer Data updated in March 2022, indicated that there were an estimated 18.1 million cancer cases around the world in 2020. Of these, 9.3 million cases were in men and 8.8 million in women. The large increase in the number of cases over the years is majorly contributing to the increase in cancer surgical therapies for efficient treatment studies, which in turn will propel the growth of the ablation devices market in the forecast period.

According to an article by the RadiologyInfo.org updated in February 2021, radiofrequency ablation (RFA), a minimally invasive treatment for cancer, employs an image-guided technique to apply heat to destroy cancer cells. RFA uses ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) to guide a needle electrode into a cancerous tumor and passes high-frequency electrical currents through the electrode to ground pads placed on the body, thereby creating focused heat that destroys the cancer cells surrounding the electrode. The article also suggested that radio frequency and microwave ablations are the most commonly used ablation treatment methods for cancer therapy.

Several market players are also focusing on ablation devices for the cancer market. For instance, in May 2022, Avenda Health's iQuest was presented at the 2022 American Urological Association annual meeting, where the retrospective study indicated that iQuest improved tumor encapsulation over conventional treatment planning from 56 percent to 80 percent. The United States Food and Drug Administration awarded the Breakthrough Device designation for the technology in May 2021 to treat prostate cancer developed by the California-based software and medical device company Avenda Health to improve cancer outcomes through artificial intelligence (AI) and minimally invasive technologies. The Avenda Health Focal Therapy System is artificial intelligence (AI)-enabled focal therapy system being developed to treat localized prostate cancer under local anesthesia. Along with AI-based margin prediction algorithms, which rely on a large database of imaging and pathology, the device uses a laser and a proprietary optical and thermal sensor to precisely target and treat just the prostate tumor. The goal of this targeted ablation device is to minimize the impact on healthy tissues without compromising other bodily functions. Such research and developments in ablation devices are expected to propel market growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period (2022 - 2027).

The rise in the adoption of highly advanced techniques and systems in the manufacturing of ablation devices and the technological advancements made in ablation device studies is expected to boost the growth of the market in the North American region. The high awareness among the population on the availability of innovative ablation device therapies in the market contributes to the high market growth in the region.

The rising number of chronic disease cases in the North American region is adding to the growth of the Ablation Devices market.​ Cancer is one of the top ten leading causes of death in the United States. According to the GLOBOCAN 2020 report, the total number of people in the United States affected by cancer in 2020 accounts for around 2,281,658 cases. The number is estimated to rise to 3,123,452 cases by 2040. ​According to the National Diabetes Statistics Report, updated in January 2022, around 37.3 million people in the United States were found to have diabetes; around 96 million adults were found to have pre-diabetes. ​The National Kidney Foundation 2021 has estimated that about 37 million adults in the United States have chronic kidney diseases. ​A report by the Centers for Disease Prevention and Control in 2020 showed that around 15.7 million Americans are affected by chronic lower respiratory Disease.​The large population affected by chronic diseases and the increase in the necessity of ablation devices for the ease of diagnosis and treatment of such diseases is expected to propel the growth of the ablation devices market.​

Also, the rise in the development of innovative ablation devices in the region is also adding to the growth of the market. For instance, in July 2020, the United States Food and Drug Administration granted Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy, developed by Ethicon, a part of the Johnson & Johnson Medical Devices Company. Such innovations in the ablation devices and the rise in approval by regulatory bodies are likely to boost the growth of the ablation devices market over the forecast period.

Thus the increasing necessity for ablation devices coupled with increasing investment in the health care department is known to propel the growth of the market in this region.

Ablation Devices Market Competitor Analysis

The global ablation device market is moderately competitive and consists of a few major players. Companies like Abbott, AngioDynamics, Inc., AtriCure, Inc., Boston Scientific Corporation, BTG plc, Conmed Corporation, Johnson and Johnson, Medtronic PLC, Olympus Corporation, Smith & Nephew PLC, among others, hold a substantial market share in the Ablation Devices market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the Prevalence of Chronic Diseases
    • 4.2.2 Technological Advancements
    • 4.2.3 Emergence of Next-generation Ablation Products and Technology
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Device
    • 4.3.2 Lack of Awareness and Stringent Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Device Technology
    • 5.1.1 Radiofrequency Devices
    • 5.1.2 Laser/Light Ablation
    • 5.1.3 Ultrasound Devices
    • 5.1.4 Cryoablation Devices
    • 5.1.5 Other Devices
  • 5.2 By Application
    • 5.2.1 Cancer Treatment
    • 5.2.2 Cardiovascular Disease Treatment
    • 5.2.3 Ophthalmologic Treatment
    • 5.2.4 Gynecological Treatment
    • 5.2.5 Urological Treatment
    • 5.2.6 Cosmetic Surgery
    • 5.2.7 Others
  • 5.3 By End-Users
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Alcon Laboratories
    • 6.1.3 AngioDynamics, Inc.
    • 6.1.4 AtriCure, Inc.
    • 6.1.5 Bausch & Lomb Incorporated
    • 6.1.6 Biotronik
    • 6.1.7 Boston Scientific Corporation
    • 6.1.8 Conmed Corporation
    • 6.1.9 Johnson and Johnson
    • 6.1.10 Medtronic PLC
    • 6.1.11 Olympus Corporation
    • 6.1.12 Smith & Nephew PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS